India · Delayed Price · Currency is INR Mankind Pharma Statistics
Total Valuation
Mankind Pharma has a market cap or net worth of INR 984.02 billion. The enterprise value is 1.05 trillion.
| Market Cap | 984.02B |
| Enterprise Value | 1.05T |
Important Dates
The next estimated earnings date is Thursday, November 6, 2025.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | Aug 8, 2025 |
Share Statistics
| Current Share Class | 412.76M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +1.63% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 57.72% |
| Owned by Institutions (%) | 19.87% |
| Float | 106.26M |
Valuation Ratios
The trailing PE ratio is 51.99 and the forward PE ratio is 43.93.
| PE Ratio | 51.99 |
| Forward PE | 43.93 |
| PS Ratio | 7.62 |
| PB Ratio | 6.75 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 55.28 |
| EV / Sales | 8.10 |
| EV / EBITDA | 33.47 |
| EV / EBIT | 42.22 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.58 |
| Debt / EBITDA | 2.73 |
| Debt / FCF | n/a |
| Interest Coverage | 4.25 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 9.38% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 4.79M |
| Profits Per Employee | 701,605 |
| Employee Count | 26,978 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Mankind Pharma has paid 4.83 billion in taxes.
| Income Tax | 4.83B |
| Effective Tax Rate | 20.15% |
Stock Price Statistics
The stock price has decreased by -9.36% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -9.36% |
| 50-Day Moving Average | 2,507.15 |
| 200-Day Moving Average | 2,462.94 |
| Relative Strength Index (RSI) | 35.93 |
| Average Volume (20 Days) | 6,479 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Mankind Pharma had revenue of INR 129.10 billion and earned 18.93 billion in profits. Earnings per share was 46.42.
| Revenue | 129.10B |
| Gross Profit | 90.06B |
| Operating Income | 24.66B |
| Pretax Income | 23.95B |
| Net Income | 18.93B |
| EBITDA | 31.03B |
| EBIT | 24.66B |
| Earnings Per Share (EPS) | 46.42 |
Balance Sheet
The company has 25.25 billion in cash and 85.11 billion in debt, giving a net cash position of -59.87 billion.
| Cash & Cash Equivalents | 25.25B |
| Total Debt | 85.11B |
| Net Cash | -59.87B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 145.68B |
| Book Value Per Share | 347.39 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 69.76%, with operating and profit margins of 19.10% and 14.66%.
| Gross Margin | 69.76% |
| Operating Margin | 19.10% |
| Pretax Margin | 18.56% |
| Profit Margin | 14.66% |
| EBITDA Margin | 24.04% |
| EBIT Margin | 19.10% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 0.04%.
| Dividend Per Share | 1.00 |
| Dividend Yield | 0.04% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.63% |
| Shareholder Yield | -1.59% |
| Earnings Yield | 1.92% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |